The goal of this observational study is to evaluate the comprehensive clinical efficacy, cardiovascular, renal, and hepatic benefits, as well as the safety of adding Chiglitazar to SGLT-2 inhibitor therapy in adult patients with Type 2 Diabetes Mellitus (T2DM) . The main questions it aims to answer are:
What is the real-world effectiveness of Chiglitazar, when added to an SGLT-2 inhibitor, on glycemic control? What are the effects of this combination therapy on cardiovascular, renal, and hepatic outcomes? What is the overall safety of this treatment regimen?
This is a non-interventional study. Participants will be prescribed Chiglitazar or other oral antidiabetic drugs by their treating physician as part of their routine clinical care. For the purpose of this registry study, data will be collected from their regular medical follow-ups. Participants will:
Attend regular follow-up visits as part of their standard diabetes care. Have data collected from their routine clinical assessments.

Start Date18 Jul 2026

Sponsor / Collaborator

Shenzhen Chipscreen Biosciences Co., Ltd.

NCT07519265

/ Not yet recruitingNot Applicable

Bioequivalence Study of Chiglitazar/Metformin Extended-Release Fixed Dose Combination Tablets in Healthy Subjects: A Randomized, Open-Label, Two-Period, Single-dose, Crossover Trial Under Fed Conditions

This is a single-center, randomized, open-label, two-period, two-sequence crossover bioequivalence study under fed conditions. The primary objective is to evaluate the bioequivalence of a single oral dose of the test formulation compared with the reference formulation in the fed state.

Start Date09 Jul 2026

Sponsor / Collaborator

Shenzhen Chipscreen Biosciences Co., Ltd.

ChiCTR2600125944

/ Not yet recruitingPhase 4IIT

Science and Technology Cooperation Project between Pengzhou People's Hospital and Southwest Medical

Start Date01 Jun 2026

Sponsor / Collaborator-

100 Clinical Results associated with Chiglitazar Sodium

100 Translational Medicine associated with Chiglitazar Sodium

100 Patents (Medical) associated with Chiglitazar Sodium

223

Literatures (Medical) associated with Chiglitazar Sodium

01 Jun 2026·BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Chiglitazar prevents diabetes-induced skeletal muscle loss by enhancing myogenic differentiation through the MEK/ERK pathway

Article

Author: Zhou, Yuxin ; Dong, Yanxin ; Xu, Fengping ; Wang, Xiaohui ; Jiang, Bei ; Li, Qiu ; Song, Wenting

Long-term diabetes markedly impairs skeletal muscle mass and function, contributing to adverse clinical outcomes. Chiglitazar (CHI), a pan-PPAR agonist, effectively reduces blood glucose levels and suppresses lipid synthesis. This study examined the protective effects of CHI against muscle loss in type 2 diabetes (T2D) using clinical data and an in vitro model involving C2C12 myoblasts cultured under high-glucose (HG) conditions. In vivo efficacy was evaluated in db/db mice. Clinical analyses revealed that CHI improves muscle quality and strength. In vitro, HG conditions inhibited myotube fusion, whereas CHI counteracted this suppression by upregulating key molecules involved in myogenic differentiation. RNA sequencing suggested that CHI exerts its protective influence through phosphorylation of the MEK/ERK signaling pathway-a finding corroborated by Western blot. Moreover, treatment with U0126, a selective MEK/ERK inhibitor, substantially attenuated the protective effects of CHI on myoblast differentiation, underscoring the essential role of this pathway. In db/db mice, CHI alleviated diabetes-related muscle loss and enhanced grip strength. These results indicate that CHI protects against diabetes-induced muscle loss by promoting myogenic differentiation via the MEK/ERK pathway, supporting its potential as a therapeutic intervention.

01 May 2026·HEPATOLOGY

Chiglitazar in MASLD with hypertriglyceridemia and insulin resistance: A phase II, randomized, double-blind, placebo-controlled study

Article

Author: Mao, Xiaorong ; Yu, Zujiang ; Shi, Junping ; Liu, Yali ; Nan, Yuemin ; Li, Yue ; Li, Zhibin ; Zhang, Qin ; Yu, Chaohui ; Chen, Bo ; Sheng, Huiping ; Wu, Cuisong ; Wu, Lixian ; Zhong, Bihui ; Xin, Yongning ; Sun, Weiwei ; Wu, Xiaofeng ; Xin, Guijie ; Shang, Jia ; Zhu, Yueyong ; Du, Jian ; Tong, Xiaofei ; Gao, Yufeng ; Sun, Yameng ; Wu, Xiaoning ; Zhao, Yingren ; Rao, Huiying ; Cao, Haixiang ; You, Hong ; Xu, Jie

Background and Aims::

Metabolic dysfunction–associated steatotic liver disease (MASLD) can progress to severe forms such as metabolic dysfunction–associated steatohepatitis (MASH). Effective treatments for MASH are urgently needed. This study aimed to evaluate the efficacy and safety of chiglitazar, a PPAR pan-agonist, in MASLD with hypertriglyceridemia and insulin resistance.

Approach and Results::

In this phase II multicenter, randomized, double-blind and placebo-controlled study, 104 patients with MASLD with hypertriglyceridemia and insulin resistance were randomized 2:2:1 to receive 48 mg, 64 mg of chiglitazar, or placebo once daily for 18 weeks. The primary endpoint was the percentage change in liver fat content measured by magnetic resonance imaging proton density fat fraction (MRI-PDFF) at week 18. Chiglitazar significantly reduced liver fat content, with percentage change from baseline at week 18 of −28.1% (95% CI −37.5 to −18.7) in the 48 mg group and −39.5% (95% CI −49.0 to −30.0) in the 64 mg group, compared with −3.2% (95% CI −16.8 to 10.4) in placebo group. The differences compared with placebo were −24.9% ( p <0.05) for the 48 mg group and −36.3% ( p <0.001) for the 64 mg group. Chiglitazar also significantly improved liver injury-related biomarkers such as ALT, AST, and γ-GT. Liver fibrosis indicators, lipid parameters, insulin resistance, and metabolic syndrome showed an improved trend. Both doses of chiglitazar were well tolerated, with most adverse events being mild to moderate.

Conclusions::

Chiglitazar significantly reduced liver fat content in MASLD with hypertriglyceridemia and insulin resistance, with a dose-dependent effect and a favorable safety profile.

01 May 2026·BMJ Open

Chiglitazar in combination with anti-inflammatory and hepatoprotective therapy for the treatment of MASH associated with T2DM: a prospective, multicentre, randomised, double-blind, placebo-controlled study protocol

Article

Author: Liu, Lianyong ; Wang, Yan ; Jiang, Wanjun ; Li, Hai ; Wu, Hong ; Zhao, Yunxin ; Chen, Fengyuan ; Lu, Yawen ; He, Kai ; Gan, Yunxia ; Huang, Zeyu ; Abuduaini, Adila ; Gao, Lingling ; Ji, Peixuan ; Zhang, Bei ; Yao, Chen ; Shao, Rong ; Bian, Yuexiang ; Shen, Chaoyun ; Wei, Jianyi ; Yan, Xiaoyan ; Gu, Wenyi

Introduction:

Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), is the hepatic manifestation of the metabolic syndrome. When it co-occurs with type 2 diabetes (T2DM), it presents a significant therapeutic challenge due to a higher risk of fibrosis progression and adverse outcomes. While new treatments for MASH are emerging, their efficacy in the T2DM subpopulation remains an unmet need. Chiglitazar is a novel peroxisome proliferator-activated receptor pan-agonist that regulates key pathways in lipid metabolism, glucose homeostasis and inflammation. This trial aims to evaluate the efficacy and safety of chiglitazar as a combination therapy for patients with MASH and T2DM.

Methods and analysis:

This is a prospective, multicentre, randomised, double-blind, placebo-controlled study. This trial will enrol 300 adult patients aged 18–75 years with biopsy-confirmed MASH and fibrosis stage F1 or higher. Participants will be randomised (1:1) to receive either chiglitazar 48 mg daily or a matching placebo. All participants will also receive background therapy consisting of vitamin E (100 mg three times a day) and polyene phosphatidyl choline (456 mg three times a day). The treatment duration is 78 weeks. The primary efficacy endpoint is resolution of steatohepatitis with no worsening of liver fibrosis. Key secondary endpoints include improvement in liver fibrosis by at least one stage and changes in metabolic and liver safety biomarkers.

Ethics and dissemination:

Ethical approval has been obtained from the Shanghai Punan Hospital of Pudong New District Ethics Committee (Punan Branch of Renji Hospital Ethics Committee, Shanghai Jiaotong University School of Medicine). KY2025-066. The findings will be disseminated through publication in peer-reviewed journals and presentations at scientific conferences.

Trial registration number:

NCT07303803 .

News (Medical) associated with Chiglitazar Sodium

15 Oct 2024

·www.biospace.com

Chiglitazar for the Treatment of MASH Phase II Clinical Study Selected for Oral Presentation at the 2024 American Liver Disease Annual Meeting

SHENZHEN, China , Oct. 15, 2024 /PRNewswire/ -- On October 15, 2024 , the list of selected candidates for the oral report of the American Association for the Study of the Liver (AASLD 2024) annual meeting was officially announced online. The abstract of the Phase II clinical study (CGZ203 trial) on the treatment of non-alcoholic steatohepatitis (NASH)/metabolic associated steatohepatitis (MASH) with our independently developed Chiglitazar (Carfloglitazar) will be presented orally at the annual meeting to be held in San Diego , USA from November 15th to 19th . The incidence of metabolic associated fatty liver disease (MAFLD) in China is over 25%, of which about 25% of patients will further develop MASH. Among patients with metabolic syndrome, this proportion is even higher. However, Currently, there is only one approved thyroid hormone receptor beta (THR - β) agonist drug in the global regulated market for the treatment of MASH. China has not yet approved any drugs for this treatment field. CGZ203 is a randomized, double-blind, placebo-controlled, phase II clinical trial aimed at evaluating the safety and preliminary efficacy of Chiglitazar (Carfloglitazar) monotherapy in the MASH population. Patients clinically diagnosed with MASH were randomly assigned to receive Chiglitazar 48mg (n=42), 64mg (n=41), or placebo (n=21) at a ratio of 2:2:1, orally once daily for a treatment period of 18 weeks. The study results showed that the liver fat content (LFC) evaluated by MRI-PDFF decreased from baseline by 28.1% and 39.5% respectively after 18 weeks of treatment with Chiglitazar 48mg or 64mg (decrease of 3.2% in the Placebo). The proportion of patients achieved over 30% decrease in LFC was 40.5% and 65.9% respectively (14.3% in the placebo). The plasma biochemical indicators related to chronic inflammation and liver injury, such as CK-18, liver transaminase, bilirubin, etc., also significantly decreased after treatment with Chiglitazar. The alanine aminotransferase (ALT) level in the high-dose group decreased by more than 50% from baseline, and the ALT level returned to the normal range in more than 70% of patients. Regarding to liver fibrosis evaluated by Fibroscan LSM, Chiglitazar produced a dose - and time-dependent decrease in liver stiffness values, with the high-dose group showing a decrease of 2 Kpa in LSM values after 18 weeks of treatment. When comparing with the placebo, Chiglitazar groups showed comparable good safety. In terms of potential side effects related to PPAR agonists, there was no significant body weight gain in the Chiglitazar treatment groups, whiles a slight decrease in the high-dose group; and only one mild edema occurred in the low-dose group. This study demonstrates the good safety tolerance and preliminary promising efficacy of Chiglitazar on the multiple pathological aspects such as liver fat accumulation, chronic inflammation, and liver fibrosis in patients with MASH, although, it remains to be confirmed in further clinical trials. ABSTRACT PRESENTATION DETAILS Abstract Number: 2603 Session Date / Time: 11/17/2024，2: 00pm - 3:30 pm Title: MASLD and MASH - New Therapies Type: Abstract Parallel Speaker: Professor You Hong, Beijing Friendship Hospital Affiliated to Capital Medical University Presentation: A randomized, double-blind, placebo-controlled phase 2 trial to evaluate the efficacy and safety of Chiglitazar in NASH patients Presentation Time: 2:15 pm - 2:30 pm Presentation Duration: 15 minutes Publication Number: 54 About Chiglitazar: Chiglitazar is a new mechanism hypoglycemic drug independently developed by the company, and also the first fully PPAR agonist approved to treat type 2 diabetes in the world. At present, Chiglitazar sodium has been approved for blood glucose control in adult patients with type 2 diabetes. It can be taken alone or combined with metformin.The Phase II clinical study of monotherapy for the treatment of nonalcoholic steatohepatitis (NASH) has concluded and achieved its primary endpoint. Chiglitazar Sodium targets insulin resistance, a core mechanism in the occurrence and development of type 2 diabetes mellitus (T2DM). It moderately activates all three PPAR subtypes to achieve a dynamic balance of glucose, lipid, energy, and protein metabolism. Preliminary comprehensive clinical studies indicate that Chiglitazar Sodium has excellent safety, pharmacokinetic, and pharmacodynamic pro demonstrating efficacy in regulating blood glucose, blood lipids, and energy in patients with T2DM. About Chipscreen: Chipscreen Biosciences is an innovative drug company driven by core technologies with globally competitive pipelines. As a pioneer in drug innovation & development in China , adhering to the concept of “Constant Innovation for Life”, we focus on developing revolutionary innovative drugs with new mechanisms of action, to address patients’ pressing clinical needs. Our complete industry chain that covers early exploratory discovery through commercialization allows us to provide innovative Chinese drugs for patients worldwide. With a global development strategy based on early-stage research in China , Chipscreen Biosciences has leveraged the top scientists and teams with extensive experience in related fields from the Shenzhen Small Molecule Early R&D Center and Chengdu Small Molecule Early R&D Center to create an integrated technology platform based on AI-driven design and chemical genomics, which spanned the whole process from basic science to clinical translation. We have successfully developed first-in-class and best-in-class innovative drugs. Currently, 2 drugs with 6 indications have been marketed worldwide. In addition, we have launched a number of R&D projects with differentiated advantages and global competitiveness in the five major areas, including malignant tumors, metabolic diseases, autoimmune diseases, central nervous system diseases, and antivirals. Chipscreen Biosciences has formed a global industrial layout consisting of Shenzhen Head Office/R&D Center/GMP production base, Chengdu Regional Head Office/R&D Center/GMP production base, Beijing Branch, Shanghai Branch, and Chipscreen Biosciences ( USA ) Co., Ltd. Meanwhile, as one of the first batches of national “innovative drug incubation bases” and national high-tech enterprises, Chipscreen Biosciences has independently undertaken many national “863" plans and national major science and technology projects, such as “10th five-year plan”, “11th five-year plan”, “12th five-year plan” and “13th five-year plan”, and National Science and Technology primary Project for Innovative Drug Development. We have filed over 660 invention patents in China and worldwide, with over 180 granted. View original content: SOURCE Shenzhen Chipscreen Biosciences, Ltd.

Clinical ResultPhase 2Drug Approval

19 Jul 2024

·www.prnewswire.com

Treatment of Type 2 diabetes with Chiglitazar combined with Metformin Approved for listing by the National Medical Products Administration

SHENZHEN, China, July 19, 2024 /PRNewswire/ -- On July 19, Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as "Chipscreen Biosciences") announced that it has received the Drug Registration Certificate approved and issued by the National Medical Products Administration (NMPA) for Chiglitazar, a noval PPAR (Peroxidase Proliferator Activated Receptor) full agonist developed by the company's independently, combined with Metformin for the treatment of type 2 diabetes. This is a further expansion of the clinical application of Chiglitazar after it was approved as a single agent for the treatment of type 2 diabetes in October 2021, and will provide a noval therapeutic option of combination for type 2 diabetes patients. As of 2021, the number of diabetes patients in China has reached 141 million, ranking first globally. Type 2 diabetes accounts for more than 90% of the total. As a progressive disease, it seriously affects the quality of life of patients and causes a heavy burden on society. As the disease progresses, the probability of monotherapy failure in type 2 diabetic patients gradually increases. Researches have shown that 50% of newly diagnosed T2DM patients require combination therapy after three years of treatment for patients with initial diabetes; After 9 years of treatment, 75% of patients require combination therapy; In addition, for newly treated patients with high blood glucose levels, such as HbA1c>9%, combination therapy is often necessary to achieve good glycemic control. Therefore, combination therapy is essential for diabetes patients. Insulin resistance, as one of the important pathological mechanisms of the occurrence and development of type 2 diabetes, has always been a focus and challenge of drug development and clinical treatment. It will not only cause hyperglycemia but also lead to hyperlipidemia, overweight/obesity, fatty liver, atherosclerotic cardiovascular disease, etc. Now, Chiglitazar has been approved for adjunction to metformin to improve glycemic control in patients with type 2 diabetes with poor blood glucose control after metformin monotherapy. The randomized, double-blind, placebo-controlled pivotal Phase III clinical trial showed that compared with placebo combined with metformin, Chiglitazar combined with metformin can achieve more clinical benefits such as continuous glucose reduction, blood lipid regulation and cardiovascular risk reduction, which shows the promising application of Chiglitazar in combination with diabetes drugs of different mechanisms. Dr. Xianping Lu, chairman of Chipscreen, said: "Although there are multiple drugs available for the treatment of T2DM, the rapid growth of the number of patients with diabetes indicates that there are still significant unmet clinical needs in this field, whether it is monotherapy or combination therapy. As the first PPAR full agonist approved to treat type 2 diabetes in the world, Chiglitazar with a new mechanism of action has broken the long-term dilemma of etiological treatment of insulin resistance, effectively targeted the metabolic syndrome caused by metabolic disorder, opening up a new path for the treatment of type 2 diabetes and providing clinicians and patients with a more flexible and effective combination drug regimen. About Chiglitazar Chiglitazar (Shuangluoping ®/ Bilessglu ®) is a new mechanism hypoglycemic drug independently developed by Shenzhen Chipscreen Biosciences Co., Ltd. As a new chemical molecule，it belongs to a national Class 1 new drug, national "Major New drug creation" special achievement . It is the first PPAR full agonist which approved for the treatment of type 2 diabetes in the world. Chiglitazar can control blood glucose level and ameliorate the lipid and energy metabolic disorders that accompany T2DM, helping to prevent and control cardiovascular complications. This makes Chiglitazar a potentially more comprehensive treatment option for T2DM. Many basic studies have confirmed that insulin resistance is one of the core pathological mechanisms for the occurrence and development of type 2 diabetes, and it is also the common soil for various metabolic abnormalities such as blood sugar and blood lipid. Insulin resistance will not only cause hyperglycemia, but also lead to hyperlipidemia, overweight/obesity, fatty liver, atherosclerotic cardiovascular disease (ASCVD), etc. However, there are relatively few drug options directly targeting the improvement of insulin resistance in clinical practice. Chiglitazar, a PPAR total agonist, can moderately activate three PPAR receptor subtypes with different functions in regulating glucose, lipid and energy metabolism in vivo, and selectively changes a series of gene expressions related to insulin sensitivity, targeting insulin resistance, the core pathological mechanism of the occurrence and development of type 2 diabetes. Through improving the sensitivity of diabetes patients to insulin, regulating blood sugar, improving their complicated lipid metabolism disorder, potentially reducing the occurrence and harm of cardiovascular complications, bringing better efficacy and safety, and achieving comprehensive treatment of diabetes and its complications. In addition to the indications for type 2 diabetes, Chiglitazar has also carried out clinical exploration of compound preparations of diabetes drugs (metformin-chiglitazar compound, Empagliflozin-chiglitazar compound) and phase II clinical research of single drug treatment of nonalcoholic fatty liver steatohepatitis in China. In October 2021, Chiglitazar was approved by the National Drug Administration (NMPA) to be marketed for the treatment of type 2 diabetes. In January 2023, Chiglitazar was included in the national medical insurance directory. In March 2024, the Phase II clinical trial (CGZ203 study) of Chiglitazar monotherapy for non-alcoholic steatohepatitis achieved the primary efficacy endpoint. In July 2024, the treatment of type 2 diabetes patients with poor blood glucose control after single drug treatment of metformin with Chiglitazar and metformin was approved for marketing by the National Drug Administration (NMPA) of China. About Chipscreen Chipscreen Biosciences is an innovative drug company driven by core technologies with globally competitive pipelines. As a pioneer in drug innovation & development in China, adhering to the concept of "Constant Innovation for Life", we focus on developing revolutionary innovative drugs with new mechanisms of action, to address patients' pressing clinical needs. Chipscreen Biosciences has formed a complete industrial chain covers from early exploratory discovery to commercialization, providing original Chinese new drugs for global patients. Based on the global development strategy of China's early stage research, Chipscreen Biosciences has been able to open the whole process from basic research to clinical transformation with Shenzhen Small Molecule Early R&D Center and Chengdu Small Molecule Early R&D Center bringing together top scientists and teams with senior experience in related fields, and applying the integrated technology platform based on AI-driven design and chemical genomics. We have successfully developed first-in-class and best-in-class innovative drugs. Currently, we have marketed two drugs for four indications in Mainland China, two indications in Japan, and one indication in Taiwan, China. In addition, we have launched a number of R&D projects with differentiated advantages and global competitiveness in the five major areas, including malignant tumors, metabolic diseases, autoimmune diseases, central nervous system diseases, and antivirals. Chipscreen Biosciences has formed a global industrial layout consisting of Shenzhen Head Office/R&D Center/GMP production base, Chengdu Regional Head Office/R&D Center/GMP production base, Beijing Branch, Shanghai Branch, and Chipscreen Biosciences (USA) Co., Ltd. Meanwhile, as one of the first batches of national "innovative drug incubation bases" and national high-tech enterprises, Chipscreen Biosciences has independently undertaken many national "863" plans and national major science and technology projects, such as "10th five-year plan", "11th five-year plan", "12th five-year plan" and "13th five-year plan", and National Science and Technology primary Project for Innovative Drug Development. We have filed over 660 invention patents in China and worldwide, with over 180 granted. SOURCE Shenzhen Chipscreen Biosciences Co., Ltd.

Drug ApprovalPhase 2Phase 3

18 Mar 2024

·www.fiercebiotech.com

Chinese biotech's MASH candidate reduces liver fat in phase 2 trial

Chiglitazar has already been approved in China as a treatment for type 2 diabetes in addition to diet and exercise, with Chipscreen looking to expand its use in combination with anti-diabetic drug metformin. Chipscreen Biosciences' metabolic dysfunction-associated steatohepatitis (MASH) candidate reduced patients' liver fat levels, adding further momentum to drugs aimed at the condition. The Shenzhen, China-based biotech says chiglitazar produced “significant and dose-dependent reductions” in liver fat content from baseline compared to placebo during a phase 2 study, according to a Monday press release. The company did not provide data to support the primary endpoint win and said more will be revealed at an upcoming conference or in a medical journal. Chipscreen also reported that patients given chiglitazar “showed significant or dose-dependent trend of improvements” on a number of secondary endpoints. As for safety, Chipscreen kept it short and sweet: “The overall safety is good.” Chiglitazar has already been approved in China as a treatment for type 2 diabetes in addition to diet and exercise, with Chipscreen looking to expand its use in combination with anti-diabetic drug metformin. The sampling of phase 2 data teased Monday comes days after Madrigal Pharmaceuticals scored the first-ever FDA approval to treat MASH, which has previously been known as non-alcoholic steatohepatitis (NASH). The much-hyped class of GLP-1 medications have also shown promise as potential MASH treatments. Chipscreen’s metabolic ambitions have grown in parallel with the biotech’s oncology work, centered on its epigenetic modulator, chidamide. The drug is approved in China as a treatment for peripheral T-cell lymphoma and breast cancer, with ongoing trials testing it in patients with diffuse large B cell lymphoma and non-small cell lung cancer.

Drug ApprovalClinical ResultPhase 2

100 Deals associated with Chiglitazar Sodium

External Link

KEGG	Wiki	ATC	Drug Bank
D12484	-	-	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	China	Chengdu Chipscreen Pharmaceutical Ltd.	22 Oct 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Insulin Resistance	Phase 2	China	Shenzhen Chipscreen Biosciences Co., Ltd.	21 Mar 2022
Metabolic Dysfunction Associated Steatohepatitis	Phase 2	China	Shenzhen Chipscreen Biosciences Co., Ltd.	21 Mar 2022
Diabetes Mellitus	Phase 1	China	Shenzhen Chipscreen Biosciences Co., Ltd.	19 Nov 2015
Depressive Disorder	Preclinical	China	Shanghai University	28 Apr 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04807348 (RECAM, Pubmed \| Diabetes Obes Metab)	Phase 3	Diabetes Mellitus, Type 2	533	Metforminar 32 mg + Metformin	qlhzwotqzn(scbbbajeii): P-Value = 0.008 View more	Positive	01 Nov 2025
				Metforminar 48 mg + Metformin
NCT05193916 (NEWS) Manual	Phase 2	Metabolic dysfunction-associated steatotic liver disease	104	48 mg 西格列他钠	fmsueucgsy(yjkwteajpp) = sgjqmqpakv foaioidapa (ltkhkfwaea ) View more	Positive	07 Aug 2025
				64 mg 西格列他钠	fmsueucgsy(yjkwteajpp) = jwtizezziq foaioidapa (ltkhkfwaea ) View more
Pubmed \| Hepatology Manual	Phase 2	Hypertriglyceridemia \| Metabolic dysfunction-associated steatotic liver disease	104	Chiglitazar 48 mg	nrmvxsyruv(aouaouuhxx) = sjwhksjzfo dfrmgxuoxu (cgqtdddzch, -37.5 to -18.7)	Positive	28 Jul 2025
				Chiglitazar 64 mg	nrmvxsyruv(aouaouuhxx) = gxwdxshxag dfrmgxuoxu (cgqtdddzch, -49.0 to -30.0)
NCT05193916 (CGZ203, Biospace) Manual	Phase 2	Metabolic Dysfunction Associated Steatohepatitis	104	Chiglitazar 48mg	hbherspfja(vhotldglnw) = izgftfkwrd mfzuwnmopw (rhwohvllwe ) View more	Positive	15 Oct 2024
				Chiglitazar 64mg	hbherspfja(vhotldglnw) = ejppoinykp mfzuwnmopw (rhwohvllwe ) View more
NCT05193916 (CGZ203, PRNewswire) Manual	Phase 2	Metabolic Dysfunction Associated Steatohepatitis	-	Carfloglitazar low dose	bkvletyspg(ngultfnewb) = Preliminary results showed that both dose groups of chiglitazar produced significant and dose-dependent reductions at the primary efficacy endpoint (the proportion of changes from baseline in liver fat content evaluated by MRI-PDFF after 18 weeks of treatment), compared to placebo control group. bwpggaiqtr (dwagjwrcfq ) Met View more	Positive	18 Mar 2024
				Carfloglitazar high dose
NCT04807348 (RECAM study, EASD2023)	Phase 3	Diabetes Mellitus, Type 2 Add-on	533	Chiglitazar 32 mg	eouvnoenex(ryemyflusl) = ruhuvyjbwk txkmfidbvw (wdqdijxmxv, -0.60 to -0.25) View more	Positive	05 Oct 2023
				Chiglitazar 48 mg	wnkajafvgi(qvcalzhque) = gkqyhwazrd zemrxzdidz (bmgiuwfyiu )
CMAS (Pubmed \| Sci Bull (Beijing))	Phase 3	Diabetes Mellitus, Type 2	-	Chiglitazar 32 mg	qqcbbawxid(qejwwcymwz) = yrkczfnumt bdwihmofpo (isbfvtwqym )	Positive	01 Aug 2021
				Chiglitazar 48 mg	qqcbbawxid(qejwwcymwz) = wfkfqpvkfu bdwihmofpo (isbfvtwqym )
NCT02173457 \| NCT02121717 (not available, EASD2020)	Phase 3	Diabetes Mellitus, Type 2 insulin resistance \| plasma TG \| HOMA-IR ... View more	1,274	Chiglitazar 32 mg	wbjrzrzdmt(jyaauklnst) = It suggested a size shift of LDL particles from small dense to less atherogenic larger one kkoxcuwpzw (xwuqqdegnw ) View more	Positive	23 Sep 2020
				Placebo
NCT02173457 (CMAS, ADA2019)	Phase 3	Diabetes Mellitus, Type 2	739	Chiglitazar 32 mg	czmgptfhak(pmzmhbdupb) = vflnphvajo phoyfllhdm (lnauxbmxvl, -0.22 to 0.15)	Positive	01 Jun 2019
				Chiglitazar 48 mg	czmgptfhak(pmzmhbdupb) = xmldiywtql phoyfllhdm (lnauxbmxvl, -0.27 to 0.10)
NCT02121717 (CMAP, ADA2019)	Phase 3	Diabetes Mellitus, Type 2	535	Chiglitazar 32 mg	oveaqoavlb(wygivquydn) = ghcgdupqvj xkcwtqcycg (jnmsebvjse, -1.10 to -0.65)	Positive	01 Jun 2019
				Chiglitazar 48 mg	oveaqoavlb(wygivquydn) = weyslkumsf xkcwtqcycg (jnmsebvjse, -1.29 to -0.81)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis